公开(公告)号：US20070185391A1

公开(公告)日：2007-08-09

申请号：US11645022

申请日：2006-12-22

Applicant: Timothy Morgan

Inventor： Timothy Morgan

IPC: A61B5/00 ,  A61B5/02 ,  A61B5/05

CPC classification number: A61B5/0002 ,  A61B5/7275 ,  G06F19/00 ,  G06F19/3418 ,  G16H10/20

Abstract: A diagnostic system is disclosed. In one embodiment, the system includes i) an input interface for use by a person to submit user profile data, physical data and psychological data to the system, the physical data representing heart rate, blood pressure, and other biophysical parameters of the person, the psychological data representing quality of life and needs satisfaction and other psychological parameters of the person, ii) an analyzer for processing the physical data and psychological data to generate risk profile data based on criteria data for conditions and iii) an output interface for providing risk profile displays using the risk profile data to present for the person risk levels associated with the conditions.

Abstract translation: 公开了诊断系统。 在一个实施例中，系统包括：i）用户使用的输入接口，用于向系统提交用户简档数据，物理数据和心理数据，表示人的心率，血压和其他生物物理参数的物理数据， 代表生活质量的心理数据，需要人的满意度和其他心理参数; ii）用于处理物理数据和心理数据的分析器，以根据条件的标准数据生成风险简档数据; iii）提供风险的输出界面 个人资料显示使用风险资料数据显示与该条件相关的人员风险水平。

公开(公告)号：US20070112834A1

公开(公告)日：2007-05-17

申请号：US11282444

申请日：2005-11-17

Applicant: James Farr ,  Billy Ledbetter ,  Timothy Morgan

Inventor： James Farr ,  Billy Ledbetter ,  Timothy Morgan

IPC: G06F7/00

CPC classification number: G06F17/303 ,  G06F17/30466 ,  G06F17/30498

Abstract: A method for consolidating a database in a Seibel CRM environment is presented. Bypassing the Business Object Layer (BOL) of the Seibel CRM environment, primary keys in a consolidated table are realigned such that a consolidated child table, created from two distinct databases, is able to point to reference items in a single parent table.

Abstract translation: 介绍了一种在Seibel CRM环境中整合数据库的方法。 绕过Seibel CRM环境的业务对象层（BOL），统一表中的主键重新对齐，以便从两个不同数据库创建的合并子表能够指向单个父表中的引用项。

公开(公告)号：US20050186141A1

公开(公告)日：2005-08-25

申请号：US11019121

申请日：2004-12-22

Applicant: Igor Gonda ,  Timothy Morgan ,  Nina Wilkins

Inventor： Igor Gonda ,  Timothy Morgan ,  Nina Wilkins

IPC: A61K9/12 ,  A61L9/04 ,  A61K7/42 ,  A61K9/70

CPC classification number: A61K9/12

Abstract: The present invention provides a pharmaceutical composition for transdermal delivery comprising: one or more physiologically active agents; one or more dermal penetration enhancers; a pharmaceutically acceptable carrier comprising a volatile solvent; and a hydrofluorocarbon propellent; wherein the carrier and penetration enhancers combine to provide a single-phase solution of the one or more physiologically active agents.

Abstract translation: 本发明提供了一种用于透皮递送的药物组合物，其包含：一种或多种生理活性剂; 一种或多种皮肤渗透增强剂; 包含挥发性溶剂的药学上可接受的载体; 和氢氟烃推进剂; 其中所述载体和渗透促进剂组合以提供所述一种或多种生理活性剂的单相溶液。

公开(公告)号：US20050175680A1

公开(公告)日：2005-08-11

申请号：US11004926

申请日：2004-12-07

Applicant: Timothy Morgan ,  Nina Wilkins ,  Kathryn Klose ,  Barrie Finnin ,  Barry Reed

Inventor： Timothy Morgan ,  Nina Wilkins ,  Kathryn Klose ,  Barrie Finnin ,  Barry Reed

IPC: A61K9/00 ,  A61K9/12 ,  A61K9/70 ,  A61K31/58

CPC classification number: A61K31/568 ,  A61K9/0014 ,  A61K9/12 ,  A61K9/7015 ,  A61K47/14 ,  A61K47/18 ,  Y10S514/872 ,  Y10S514/874 ,  Y10S514/946 ,  Y10S514/947

Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.

Abstract translation: 一种用于透皮递送的药物组合物，其包含一种或多种生理活性剂; 一种或多种皮肤渗透增强剂; 和包含挥发性溶剂的挥发性药学上可接受的载体; 并且其中所述生理活性剂和皮肤渗透增强剂在挥发性载体蒸发时形成无定形沉积物，所述无定形沉积物在角质层内形成储存器; 和（A）其中组合物具有生理活性剂的释放速率曲线，以提供最大浓度（C max）与平均浓度（C平均值）之比 >）在1〜1​​0的范围内的剂量间隔内的生理活性剂。